Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
38
BEAM Quote, Financials, Valuation and Earnings
Last price:
$25.13
Seasonality move
:
-16.25%
Day range:
$24.96 - $26.46
52-week range:
$13.53 - $36.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
17.89x
P/B ratio:
2.07x
Volume:
1.7M
Avg. volume:
1.8M
1-year change:
-6.67%
Market cap:
$2.6B
Revenue:
$139.7M
EPS (TTM):
-$1.02
Analysts' Opinion
-
Consensus RatingBeam Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $49.93, Beam Therapeutics, Inc. has an estimated upside of 98.46% from its current price of $26.08.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $26.00 representing 100% downside risk from its current price of $26.08.
Fair Value
-
According to the consensus of 16 analysts, Beam Therapeutics, Inc. has 98.46% upside to fair value with a price target of $49.93 per share.
BEAM vs. S&P 500
-
Over the past 5 trading days, Beam Therapeutics, Inc. has underperformed the S&P 500 by -5.7% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Beam Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Beam Therapeutics, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Beam Therapeutics, Inc. reported revenues of $114.1M.
Earnings Growth
-
Beam Therapeutics, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Beam Therapeutics, Inc. reported earnings per share of $2.33.
Enterprise value:
1.5B
EV / Invested capital:
1.06x
Price / LTM sales:
17.89x
EV / EBIT:
--
EV / Revenue:
10.53x
PEG ratio (5yr expected):
-0.05x
EV / Free cash flow:
-4.09x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$117.4M
Return On Assets:
-5.92%
Net Income Margin (TTM):
-57.24%
Return On Equity:
-7.83%
Return On Invested Capital:
-6.79%
Operating Margin:
-15.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $377.7M | $63.5M | $139.7M | $30.1M | $114.1M | |
| Gross Profit | $350.6M | $41.6M | $117.4M | $24.6M | $108.4M | |
| Operating Income | -$176.5M | -$415.6M | -$383.7M | -$100M | -$17.4M | |
| EBITDA | -$149.4M | -$393.6M | -$361.4M | -$94.6M | -$11.8M | |
| Diluted EPS | -$1.91 | -$4.58 | -$1.02 | -$1.09 | $2.33 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.3B | $1.1B | $1.2B | $878.1M | $1.3B | |
| Total Assets | $1.5B | $1.3B | $1.5B | $1.1B | $1.5B | |
| Current Liabilities | $213.4M | $223.6M | $205.6M | $182.1M | $96.9M | |
| Total Liabilities | $647.7M | $608.2M | $478.4M | $370.3M | $242.8M | |
| Total Equity | $826.7M | $733.5M | $981.3M | $733.5M | $1.2B | |
| Total Debt | $140.1M | $171.6M | $160.4M | $148M | $139.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$149.2M | -$347.2M | -$345.1M | -$76.4M | -$83.3M | |
| Cash From Investing | $71.8M | $185M | -$121.4M | $126.3M | $108.4M | |
| Cash From Financing | $276.4M | $7.7M | $478M | $3.4M | $1.9M | |
| Free Cash Flow | -$182.9M | -$356.2M | -$360M | -$79.3M | -$87M | |
BEAM
Sector
Market Cap
$2.6B
$25.1M
Price % of 52-Week High
69.05%
48.72%
Dividend Yield
0%
0%
Shareholder Yield
-16.89%
-1.6%
1-Year Price Total Return
0.4%
-18.38%
Beta (5-Year)
2.118
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$26.90
200-day SMA
Buy
Level
$23.42
Bollinger Bands (100)
Sell
Level
24 - 29.98
Chaikin Money Flow
Sell
Level
-34.3M
20-day SMA
Sell
Level
$27.71
Relative Strength Index (RSI14)
Sell
Level
43.78
ADX Line
Sell
Level
11.54
Williams %R
Buy
Level
-94.1667
50-day SMA
Sell
Level
$28.70
MACD (12, 26)
Sell
Level
-0.52
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
44.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.6069)
Sell
CA Score
(Annual)
Level (-0.5549)
Sell
Beneish M-Score
(Annual)
Level (-1.6231)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.1444)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, BEAM has received 14 Buy ratings 2 Hold ratings, and 0 Sell ratings. The BEAM average analyst price target in the past 3 months is $49.93.
-
Where Will Beam Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Beam Therapeutics, Inc. share price will rise to $49.93 per share over the next 12 months.
-
What Do Analysts Say About Beam Therapeutics, Inc.?
Analysts are divided on their view about Beam Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Beam Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $26.00.
-
What Is Beam Therapeutics, Inc.'s Price Target?
The price target for Beam Therapeutics, Inc. over the next 1-year time period is forecast to be $49.93 according to 16 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is BEAM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Beam Therapeutics, Inc. is a Buy. 14 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BEAM?
You can purchase shares of Beam Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Beam Therapeutics, Inc. shares.
-
What Is The Beam Therapeutics, Inc. Share Price Today?
Beam Therapeutics, Inc. was last trading at $25.13 per share. This represents the most recent stock quote for Beam Therapeutics, Inc.. Yesterday, Beam Therapeutics, Inc. closed at $26.08 per share.
-
How To Buy Beam Therapeutics, Inc. Stock Online?
In order to purchase Beam Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BEAM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BEAM
Sector
P/E ratio
--
21.37x
PEG ratio
-0.05x
-0.01x
P/B ratio
2.07x
1.73x
Price / LTM sales
17.89x
1.46x
Growth Metrics
BEAM
Sector
Revenue growth
279.52%
3.27%
Earnings growth
313.43%
12.13%
Revenue (5-year growth)
466.27%
6.25%
Earnings forecast
-$1.12
-$0.20
Profitability
BEAM
Sector
Profitability FY 2025
$117.4M
$2.3M
Return on invested capital
-6.79%
-33.43%
Return on assets
-5.92%
-29.94%
Return on equity
-7.83%
-40.07%
Earnings Date
Last Earnings Date
Feb
24
Next Earnings Date
May
5
Estimated Next Earnings Date
May
26
Balance Sheet
BEAM
Sector
Total cash
$1.2B
$24.9M
Short term investments
$568.8M
$23M
Total assets
$1.5B
$70.1M
Long term debt
$139.8M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
92
APEI alert for Mar 13
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
